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SUPPLEMENTARY FIGURES 
Supplementary figure 1 illustrates the CD66b expression in human lymphoid tissues. 
Supplementary figure 2 illustrates the CD66b+ TAN score in M-TDLNs and matched PT. 
Supplementary figure 3 illustrates the CD66b+ TANs localization in TDLNs. 
Supplementary figure 4 illustrates the CD66b+ TANs localization within the lymphatic sinuses. 
Supplementary figure 5 illustrates the phenotype of CD66b+ TANs in M-TDLNs and matched PT  
Supplementary figure 6 illustrates viability test of circulating neutrophils co-coltured with human 
OSCC lines 
Supplementary figure 7 details on the algorithm of the image analysis of TANs in OSCC. 
Supplementary figure 8 shows representative examples of image analysis of CD66b+ TANs in 
OSCC. 
Supplementary figure 9 illustrates cell interactions of CD66b+ TANs with immune cells in M-
TDLN. 
Supplementary figure 10 illustrates the Heatmap of pEMT genes in the TCGA dataset.  
Supplementary figure 11 shows Correlation Circle Plots for all OSCC samples of pEMT and PMN. 
Supplementary figure 12 illustrates the immunophenotypic characterization of blood leukocytes 
from OSCC patients. 
Supplementary figure 13 illustrates the immunophenotipic characterization of circulating 
neutrophils from OSCC patients. 
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SUPPLEMENTARY FIGURE 1 
 
 
Supplementary figure 1: CD66b expression in human lymphoid tissues. Sections stained for CD66b 
are from FFPE human tissues including bone marrow (A), thymus (B), spleen (C), tonsil (D), lymph 
node (E), suppurative lymphadenitis (F), ileal Peyer patch (G) and appendix (H). CD66b reactivity 
is limited to polymorphs, particularly abundant in the bone marrow (A), in the red pulp of the spleen 
(C) as well as in case of necrotizing lymphadenitis of infectious origin (F). Sections are 
counterstained with hematoxylin. Original magnification 100x (scale bar 200 µm), inset 600x. 
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SUPPLEMENTARY FIGURE 2 
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Supplementary figure 2: CD66b+ TAN score in M-TDLNs and matched PTs. Sections stained for 
CD66b are from FFPE human M-TDLNs (A-F, G, I, K) and primary tumors (H, J, L). Representative 
M-TDLN cases for score 0 (A, B), score 1 (C, D), score 2 (E, F) of CD66b+ TAN are illustrated.  The 
comparison between M-TDLNs and matched PTs is illustrated by two concordant cases of 
respectively a gastric carcinoma (G, H) and a ductal mammary carcinoma (I, J); a discordant case of 
cutaneous melanoma is instead reported in K, L. Graph shows the correlation between CD66b+ TAN 
density in M-TDLNs and their matched PTs. Sections are counterstained with hematoxylin. Original 
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SUPPLEMENTARY FIGURE 3 
 
Supplementary figure 3: CD66b+ TANs localization in TDLNs. Graphs illustrate the distribution of 
CD66b+ TANs in the lymph node compartments of M-TDLNs (black columns) and NM-TDLN 
(white columns) draining primary cutaneous melanomas and carcinomas from various sites. Sites 
analyzed are labeled in the graph titles as well as number of lymph nodes analyzed. M-TDLNM stands 
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SUPPLEMENTARY FIGURE 4 
 
Supplementary figure 4: CD66b+ TANs localization within the lymphatic sinuses. Sections are from 
FFPE human TDLNs and stained as labeled. A set of markers allow the identification of the lymphatic 
sinuses (A, D) and HEVs (B, C, F, G) or both (E). Serial sections (A-C) show that CD66b+ TANs 
are mainly confined within enlarged podoplanin+CD31-CD34- lymphatic sinuses. CD66b+ TAN are 
also observed within the HEVs lumen (F), rarely in form of transmigrating cells (arrows head, G). 
Magnification of a sinus (H) show that also CD163+ macrophages are contained within the lymphatic 
sinuses together with neutrophils (arrow heads). CD3+ T cells are also present in lymphatic sinuses 
(I). Sections are counterstained with hematoxylin. Original magnification: 100x (scale bar 200 
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SUPPLEMENTARY FIGURE 5 
 
Supplementary figure 5: Phenotype of CD66b+ TANs in M-TDLN and PT. Sections are from M-
TDLN of lung carcinoma (A, C, E, G, I) and its respective matched PT (B, D, F, H, J). Sections are 
stained for markers of neutrophils, as labeled, and counterstained with hematoxylin. TANs in the M-
TDLN and PT co-expressed the neutrophil markers (A-J). Original magnification: 400x (scale bar 50 
µm) (C-F, I, J), 600x (scale bar 33 µm)(G, H, K, L).  
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Supplementary figure 6. Bar plots showing the results of the Vybrant assay testing the viability of 
peripheral PMN from healthy donors cultured for 40h in medium or co-cultured with SCC cell lines 
(SCC-4, n=3; SCC-25, n=2 or CAL-27, n=2) (A). Dot plot using Vybrant DyeCycleTM Violet stain 
illustrating the percentage of death PMN after 40h; a representative experiment on SCC-4 cell line is 
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SUPPLEMENTARY FIGURE 7 
 
 
Supplementary figure 7: Image analysis of TANs in OSCC. Sections are from human OSCC stained 
for CD66b. Regions of interest are shown for the primary tumor (A, B), M-TDLN (C) and NM-TDLN 
(D). In the primary tumor, the center of the tumor (CT) and the invasive margin (IM) are separated 
as illustrated in a scanning view (A) and detailed at high magnification (B). In the M-TDLN, the 
uninvolved lymph node parenchyma (P) is distinct from the metastatic nest (M). Representative 
native and processed image by using Aperio ImageScope IHC nuclear algorithm. (CD66b positivity 
indicated by red color) obtained from a primary OSCC stained for CD66b are shown in E and F.  
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Supplementary Figure S8: Image analysis of CD66b+ TANs in OSCCs. Panel showing four 
representative cases of PTs and M-TDLNs OSCCs stained for CD66b. Scanning view and 100x 
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SUPPLEMENTARY FIGURE 9 
 
 
Supplementary figure 9: Cell interaction of CD66b+ TANs with immune cells in M-TDLNs. 
Sections are from human score 2 M-TDLNs and stained as labeled. Sections are counterstained with 
hematoxylin. Original magnification: 200x (scale bar 100 µm)(D, G, J), 400x (scale bar 50 µm) (A-
C, E, F, H, I). 
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SUPPLEMENTARY FIGURE 10 
 
 
Supplementary figure 10: Heatmap of pEMT signature genes (Spearman correlation distance). 
Lower panel shows the pEMT global score and the pEMT High/Low definition based on cutting the 
dendrogram in two groups. 
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Supplementary figure 11A-C: Correlation Circle Plots for all OSCC samples and separately for 
stage I and II or III and IV, following Canonical Correlation Analysis (CCA) of pEMT (red) and 
PMN (blue) signature matrices. The plot illustrate the correlation between each original variable 
(gene) and the first two canonical variates (dimensions). Genes further away from the origin and 
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Supplementary figure 12: Immunophenotypic characterization of CD45+ whole blood leukocytes 
from OSCC patients. A-G, Dot plots show the percentage of B cells (CD19+ cells; A), Tregs 
(CD4+CD127low/-CD25+ cells; B), NK cells (CD56+CD3- cells; C) monocytes (classical, cM: HLA-
DR+CD14+CD16- cells; intermediate Im: HLA-DR+CD14+CD16+ cells; non classical, ncM: HLA-
DR+CD14dim/-CD16+ cells; D), total T cells (CD3+ cells; E), pDCs (CD303+; F), and neutrophils 
(CD66b+ cells; G) within CD45+ whole blood leukocytes from HDs or OSCC patients. H, dot plot 
shows the percentage of CD10+ cells within total circulating neutrophils from HDs and OSCC 
patients. I, dot plot shows NLR of HDs or OSCC patients, calculated by dividing neutrophil count to 
lymphocyte count. Graph values indicate medians from independent experiments. Each symbol 
stands for a single HD (open circle; n = 13) or OSCC patient (black circle; n=15). ** P ≤ .01, * P ≤ 
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Supplementary figure 13: Immunophenotipic characterization of circulating neutrophils from 
OSCC patients. Panels display the levels of CD62L, CD16, CD11b, CD54, CD274, CD11c, CD11a, 
CCR7, CXCR1, CXCR2, C5aR and CXCR4 expression in neutrophils from HDs or OSCC patients, 
as evaluated by flow cytometry. For each antigen, data are expressed as median fold change (FC) of 
the MFI in neutrophils from OSCC patients over neutrophils from HDs. Graph values indicate 
medians from independent experiments. Each symbol stands for a single HD (open circle; n = 13) or 




Supplementary table 1 reports details on CD66b expression in TDLN of carcinomas from various 
primary sites. 
Supplementary table 2 reports the summary of clinical data of the retrospective OSCC cohort  
Supplementary table 3 reports the details of clinical data of the retrospective OSCC cohort 
Supplementary table 4 summarizes the digital microscopy analysis of CD66b in the OSCC cohort 
Supplementary table 5 illustrates details of the targets contained in the PMN signature. 
Supplementary table 6 reports coefficients and p-values for univariate linear models between pEMT 
and PMN genes expression. 
Supplementary table 7 reports the details of clinical data of the prospective H&N SCC cohort. 
Supplementary table 8 reports the details of antibodies used for immunohistochemistry and flow 
cytometry. 
Supplementary table 9 reports the primer pairs used for reverse transcription quantitative real-time 
PCR. 
Supplementary table 1: CD66b expression in TDLN FFPE cases of carcinomas from various primary sites. 
Site of the 
primary 
tumor 






















melanoma 17 19 19 9 (47.4) 9 (47.4) 1 (5.2) 0 0 (0) 0 (0) 
squamous carcinoma 7 24 9 0 (0) 5 (55.5) 4 (44.5) 15 2 (13.3) 13 (86.7) 
Head & Neck squamous carcinoma 20 46 28 3 (10.7) 18 (64.3) 7 (25) 18 6 (33.3) 12 (66.7) 
Thyroid 
medullary carcinoma 2 6 2 0 (0) 1 (50) 1 (50) 4 4 (100) 0 (0) 
oxyphil carcinoma 1 4 2 0 (0) 0 (0) 2 (100) 2 0 (0) 2 (100) 
papillary carcinoma 17 40 22 8 (36.4) 9 (40.9) 5 (22.7) 18 9 (50) 9 (50) 
Breast 
  
ductal carcinoma 37 69 45 34 (75.6) 10 (22.2) 1 (2.2) 24 14 (58.3) 10 (41.7) 
lobular carcinoma 1 1 1 1 (100) 0 (0) 0 (0) 0 0 (0) 0 (0) 
Lung 
squamous cell carcinoma 11 21 11 5 (45.45) 5 (45.45) 1 (9.1) 10 9 (90) 1 (10) 
adenocarcinoma 10 14 12 2 (16.65) 8 (66.7) 2 (16.65) 2 1 (50) 1 (50) 
undifferentiated carcinoma 1 1 1 0 (0) 1 (100) 0 (0) 0 0 (0) 0 (0) 
Stomach 
diffuse/undifferentiated 
carcinoma 5 11 6 3 (50) 2 (33.3) 1 (16.7) 5 4 (80) 1 (20) 
intestinal carcinoma 14 33 21 11 (52.4) 6 (28.6) 4 (19) 12 9 (75) 3 (25) 
mixed carcinoma 2 2 2 1 (50) 0 (0) 1 (50) 0 0 (0) 0 (0) 
Pancreas ductal adenocarcinoma 16 33 19 6 (31.6) 6 (31.6) 7 (36.8) 14 8 (57.2) 6 (42.8) 
Colon adenocarcinoma 25 74 42 21 (50) 13 (31) 8 (19) 32 22 (68.8) 10 (31.2) 
Bladder transitional carcinoma 12 17 12 3 (25) 6 (50) 3 (25) 5 2 (40) 3 (60) 
Ovary 
serous carcinoma 15 34 21 5 (23.8) 13 (61.9) 3 (14.3) 13 8 (61.5) 5 (38.5) 
endometrioid carcinoma 1 1 1 1 (100) 0 (0) 0 (0) 0 0 (0) 0 (0) 
mixed carcinoma 2 3 2 0 (0) 1 (50) 1 (50) 1 0 (0) 1 (100) 
TOTAL  216 453 278 113 (40.65) 
113 
(40.65) 52 (18.7) 175 98 (56) 77 (44) 
           
Legend: FFPE, formalin-fixed paraffin embedded; TDLNs, tumor draining lymph nodes; M-TDLNs, metastatic tumor draining lymph nodes; NM-TDLNs, 
nonmetastatic tumor-draining lymph nodes
Supplementary table 2:  Clinicopathological data, univariate and multivariate survival analysis of 
OSCC retrospective cohort 
Patient characteristics  Univariate survival analysis (OS) 
Variable n (%)  Variable % 5-y 
OS 
p 
All      Age < 65 67.5 0.030 
    182 (100)  ≥ 65 50.9 
Gender      Gender Male 58.7 0.465 
  Male 115 (63)  Female 65.4 
  Female 67 (37)  pT T1-T2 70.6 0.003 
Age      T3-T4 50.6 
  Mean (Range) 63,6 (26-93)  
pN/ECS 
N0 78 
<0.001 Treatment      N+/ECS- 57.3 
  Surgery 78 (43)  N+/ECS+ 27.8 




  Surgery + RT + CHT 43 (24)  III-IV 49.3 
pT stage      Surgical margins Negative 65.3 0.063 
  T1-2 91 (50)  Positive 41.8 
  T3-4 91 (50)  
Grading 
G1 67.5 
0.266 pN      G2 58.5 
  N0 97 (53)  G3 61.8 
  N+ 85 (47)  Perineural 
spread 
Absent 68.6 0.079 
ECS (Extracapsular spread)    Present 53.3 
  Present 42 (49)  Lymphovascular 
invasion 
Absent 68.6 0.001 
  Absent 43 (51)  Present 38.2 
AJCC - Stage           







    
  III-IV 120 (66)  Multivariate survival analysis (OS) 
Grading      Variable HR CI p 
  G1 18 (10)  pT 1.33 0.80-2.21 0.266 
  G2 87 (48)  
pN/ECS 
N0 1     
  G3 77 (42)  N+/ECS- 1.29 0.69-2.39 0.418 
Margins      N+/ECS+ 3.09 1.72-5.75 <0.001 
  Negative 150 (82)  Perineural spread 1.36 0.85-2.15 0.195 
  Positive 32 (18)  Lymphvascular invasion 1.37 0.83-2.26 0.214 
Perineural spread           
  Present 90 (49)       
  Absent 92 (51)       
Lymphovascular invasion         
  Present 51 (28)       
  Absent 131 (72)       
Legend: OSCC, Oral cavity Squamous Cell Carcinoma; RT, radiotherapy; CHT, chemotherapy; ECS, 
extracapsular spread; OS, overall survival; HR, hazard ratio; CI, 95% confidence interval. 





CD66b CT CD66b IM CD66b M-TDLNM CD66b M-TDLNP CD66b NM-TDLN
5 M 55 Surgery+RT pT4 pN2b Stage IV yes G3 negative absent absent dead 28 1829 2059 809 nd 131
74 M 50 Surgery+CHT-RT pT4 pN2b Stage IV yes G3 negative absent absent dead 9 1295 1028 350 96 22
16 M 60 Surgery+RT pT2 pN2b Stage IV yes G3 positive absent absent dead 18 693 nd 298 144 40
4 M 79 Surgery pT2 pN0 Stage II no G1 negative absent present dead 159 634 506 - - 166
103 F 65 Surgery+RT pT2 pN0 Stage II no G3 negative present absent dead 61 637 656 - - 224
6 M 57 Surgery+RT pT4 pN0 Stage IV no G3 negative present absent dead 99 22 98 - - 57
7 F 48 Surgery+RT pT4 pN0 Stage IV no G3 negative absent absent dead 89 242 402 - - 113
161 M 72 Surgery+CHT-RT pT4 pN2b Stage IV yes G2 positive present present dead 12 395 640 111 266 nd
9 F 69 Surgery pT2 pN0 Stage II no G2 negative absent present dead 130 283 907 - - 479
140 M 48 Surgery+CHT-RT pT4 pN1 Stage IV no G3 negative absent absent dead 9 429 234 183 55 224
152 F 81 Surgery pT4 pN1 Stage IV no G2 negative present present dead 5 310 395 34 117 101
12 M 46 Surgery pT1 pN0 Stage I no G2 negative absent present alive 163 547 720 - - 142
88 F 58 Surgery+CHT-RT pT3 pN2c Stage IV yes G2 negative absent present dead 22 371 262 24 188 66
14 M 36 Surgery+CHT-RT pT2 pN0 Stage II no G2 negative present present alive 162 983 531 - - 173
173 M 90 Surgery pT4 pN0 Stage IV no G1 negative absent present dead 11 385 291 - - 85
43 F 78 Surgery+RT pT4 pN1 Stage IV no G3 negative present absent dead 46 362 258 414 351 83
33 M 63 Surgery pT2 pN0 Stage II no G3 negative present absent dead 99 201 441 - - 324
96 M 75 Surgery+CHT-RT pT1 pN2b Stage IV yes G3 negative present absent dead 11 324 214 82 81 34
19 M 57 Surgery+RT pT2 pN0 Stage II no G3 positive absent absent alive 148 180 226 - - 81
20 F 68 Surgery pT2 pN0 Stage II no G3 negative present absent alive 144 41 78 - - 138
141 M 44 Surgery pT4 pN2c Stage IV yes G3 positive present absent dead 3 238 281 195 80 127
22 F 59 Surgery pT1 pN0 Stage I no G3 negative present absent alive 141 59 158 - - 202
23 F 72 Surgery pT2 pN0 Stage II no G3 negative present absent alive 124 71 137 - - 71
17 M 71 Surgery+RT pT2 pN2b Stage IV no G3 negative absent absent dead 19 180 314 64 203 57
25 M 75 Surgery+RT pT4 pN2b Stage IV yes G2 negative absent present alive 122 106 nd 41 103 91
26 M 62 Surgery+RT pT1 pN2b Stage IV no G2 negative absent present alive 138 72 295 72 60 108
15 M 70 Surgery+RT pT3 pN2b Stage IV yes G3 positive present absent dead 29 251 175 79 26 121
28 M 56 Surgery+RT pT4 pN2b Stage IV no G2 negative present present alive 136 25 87 13 25 136
32 F 43 Surgery pT2 pN0 Stage II no G2 negative absent present dead 18 36 514 - - 145
60 M 56 Surgery+CHT-RT pT4 pN2b Stage IV no G2 negative present present dead 7 220 236 29 114 262
31 M 76 Surgery+RT pT2 pN2a Stage IV no G3 negative absent absent dead 27 289 203 872 55 101
76 F 54 Surgery+CHT-RT pT4 pN2b Stage IV yes G3 positive present absent dead 59 230 178 124 220 128
108 M 60 Surgery pT4 pN0 Stage IV no G2 negative present present dead 32 122 415 - - 42
34 F 57 Surgery+CHT-RT pT4 pN2b Stage IV yes G3 negative absent absent dead 39 27 31 125 40 172
95 M 78 Surgery+RT pT4 pN1 Stage IV no G2 negative absent present dead 15 173 224 314 168 317
36 F 50 Surgery pT4 pN0 Stage IV no G3 negative present absent alive 134 86 462 - - 102
37 M 57 Surgery+CHT-RT pT4 pN1 Stage IV no G3 positive present absent alive 131 666 674 191 192 150
38 M 42 Surgery pT1 pN1 Stage III no G3 negative absent absent alive 130 222 150 13 66 35
39 M 38 Surgery+CHT-RT pT2 pN2b Stage IV no G3 negative absent absent alive 129 398 307 100 372 207
40 F 69 Surgery+RT pT4 pN0 Stage IV no G1 negative absent present alive 126 1471 nd - - 228
41 M 74 Surgery+RT pT4 pN2b Stage IV no G3 negative absent absent dead 112 794 1048 550 432 176
42 M 78 Surgery pT1 pN0 Stage I no G2 negative absent present alive 126 58 90 - - 74
180 M 55 Surgery+RT pT4 pN0 Stage IV no G2 negative present present dead 8 137 277 - - 76
44 M 39 Surgery+CHT-RT pT4 pN2c Stage IV no G1 negative present present alive 124 696 890 107 100 nd
45 M 63 Surgery+RT pT2 pN0 Stage II no G2 positive absent present dead 105 36 106 - - 101
46 F 63 Surgery+RT pT4 pN1 Stage IV no G2 negative absent present alive 53 110 145 133 68 89
47 M 57 Surgery+CHT-RT pT4 pN2c Stage IV no G3 negative present absent alive 121 554 789 153 102 136
48 M 64 Surgery pT2 pN1 Stage III no G3 negative absent absent alive 119 152 78 2 392 111
49 F 63 Surgery pT4 pN1 Stage IV no G1 negative absent present alive 118 92 290 67 175 60
50 F 57 Surgery pT2 pN0 Stage II no G2 negative absent present alive 116 460 965 - - 254
51 M 63 Surgery pT2 pN0 Stage II no G3 negative absent absent dead 67 144 251 - - 187
52 M 66 Surgery pT4 pN0 Stage IV no G1 negative absent present alive 116 31 87 - - 102
53 F 62 Surgery+RT pT4 pN0 Stage IV no G2 negative absent present dead 64 121 124 - - 221
54 M 44 Surgery pT2 pN0 Stage II no G3 positive absent absent dead 27 323 191 - - 28
106 M 83 Surgery+RT pT4 pN2b Stage IV yes G3 negative present absent dead 27 209 127 45 79 180
56 F 40 Surgery+RT pT2 pN1 Stage III no G3 negative absent absent alive 114 284 829 64 362 436
57 F 93 Surgery pT1 pN2b Stage IV no G3 negative present absent dead 31 190 145 189 120 162
27 F 75 Surgery+RT pT2 pN1 Stage III no G2 negative present present dead 13 171 153 9 nd 164
59 M 63 Surgery+CHT-RT pT4 pN2b Stage IV yes G3 negative present absent alive 111 32 85 25 35 39
13 F 75 Surgery+RT pT3 pN0 Stage III no G2 positive absent present dead 62 159 175 - - 72
61 F 51 Surgery pT1 pN1 Stage III no G3 negative present absent alive 107 79 66 14 24 41
62 F 64 Surgery pT2 pN0 Stage II no G2 negative present present alive 109 283 306 - - 102
63 M 65 Surgery+CHT-RT pT3 pN0 Stage III no G3 positive present absent alive 104 102 139 - - 156
64 M 65 Surgery+CHT-RT pT4 pN1 Stage IV yes G2 negative present present dead 76 163 299 109 704 610
65 F 61 Surgery pT1 pN0 Stage I no G3 negative absent absent alive 104 284 794 - - 30
66 M 70 Surgery+RT pT4 pN1 Stage IV no G3 positive absent absent alive 103 6 10 nd 518 41
67 M 70 Surgery pT2 pN0 Stage II no G2 negative absent present alive 103 87 123 - - 313
68 M 42 Surgery pT1 pN0 Stage I no G2 negative absent present alive 98 408 389 - - 249
69 M 55 Surgery pT1 pN0 Stage I no G2 negative absent present alive 99 187 158 - - 484
70 M 59 Surgery pT1 pN0 Stage I no G3 negative absent absent alive 99 109 57 - - 72
71 M 51 Surgery+CHT-RT pT4 pN1 Stage IV yes G2 negative absent present alive 98 226 131 112 31 63
104 F 78 Surgery pT4 pN0 Stage IV no G2 negative absent present dead 40 165 161 - - 318
73 F 64 Surgery pT2 pN0 Stage II no G2 negative present present alive 96 27 45 - - 95
29 F 75 Surgery+RT pT4 pN0 Stage IV no G2 negative present present dead 11 134 252 - - 127
75 M 54 Surgery pT1 pN0 Stage I no G2 negative absent present alive 93 303 215 - - 82
86 F 62 Surgery+RT pT1 pN1 Stage III no G3 negative present absent dead 27 253 98 4 232 30
77 M 74 Surgery pT1 pN0 Stage I no G2 negative absent present alive 90 162 213 - - 92
78 F 76 Surgery pT2 pN0 Stage II no G2 negative absent present alive 88 29 34 - - 96
79 M 57 Surgery pT1 pN0 Stage I no G3 negative absent absent alive 86 310 179 - - 44
80 F 88 Surgery pT2 pN0 Stage II no G2 negative absent present alive 85 325 452 - - 156
81 M 70 Surgery pT2 pN1 Stage III no G2 positive present present dead 19 260 297 174 106 480
82 F 62 Surgery+CHT-RT pT2 pN0 Stage II no G3 negative present absent alive 85 410 417 - - 252
83 M 74 Surgery pT2 pN2a Stage IV yes G2 negative present present dead 11 138 209 68 43 25
84 M 63 Surgery+CHT-RT pT3 pN2b Stage IV no G2 negative present present alive 81 177 116 51 32 80
85 M 70 Surgery pT2 pN0 Stage II no G3 negative present absent alive 80 358 343 - - 50
8 M 56 Surgery+RT pT4 pN1 Stage IV yes G3 negative absent absent dead 75 87 245 19 142 295
87 M 62 Surgery pT1 pN0 Stage I no G2 positive absent present alive 77 37 79 - - 24
30 F 67 Surgery+CHT-RT pT1 pN0 Stage I no G3 negative present absent dead 16 126 143 - - 174
89 M 47 Surgery+CHT-RT pT2 pN2c Stage IV yes G2 negative present present alive 74 96 202 95 83 74
90 M 77 Surgery pT1 pN0 Stage I no G2 negative present present dead 25 54 37 - - 148
91 M 71 Surgery pT2 pN0 Stage II no G2 negative absent present alive 69 226 213 - - 90
92 F 26 Surgery pT2 pN0 Stage II no G2 negative present present alive 65 109 133 - - 542
93 M 44 Surgery+CHT-RT pT2 pN2b Stage IV yes G3 negative present absent alive 65 96 116 34 61 70
94 M 68 Surgery pT2 pN0 Stage II no G2 negative absent present alive 67 585 1050 - - 283
3 M 72 Surgery+RT pT1 pN2c Stage IV yes G2 negative absent present dead 12 116 163 146 90 32
1 M 61 Surgery+RT pT4 pN2b Stage IV yes G3 negative absent absent dead 8 136 125 54 32 33
97 M 74 Surgery pT2 pN0 Stage II no G3 negative absent absent dead 13 338 965 - - 186
149 M 75 Surgery+RT pT4 pN1 Stage IV no G2 positive present present dead 20 122 nd 83 103 145
99 F 54 Surgery pT4 pN0 Stage IV no G2 negative absent present alive 64 179 218 - - 166
130 F 81 Surgery pT4 pN2c Stage IV yes G2 negative present present dead 7 134 89 170 77 67
164 F 61 Surgery+CHT-RT pT4 pN2b Stage IV yes G2 negative present present dead 19 88 192 31 68 102
102 M 45 Surgery pT2 pN0 Stage II no G2 negative absent present alive 62 1274 1002 - - 89
2 M 52 Surgery+RT pT4 pN2b Stage IV no G2 negative present present dead 16 82 168 33 42 33
120 M 74 Surgery+RT pT4 pN2b Stage IV yes G2 negative present present dead 7 114 116 104 42 61
105 M 48 Surgery pT1 pN0 Stage I no G2 positive absent present alive 59 93 61 - - 259
Supplementary table 3:  Details of clinical data of the retrospective OSCC cohort.
122 M 43 Surgery+RT pT1 pN0 Stage I no G1 negative present present dead 49 132 75 - - 83
107 M 81 Surgery+RT pT4 pN2b Stage IV yes G3 positive present absent dead 2 319 330 631 217 133
162 F 48 Surgery+CHT-RT pT4 pN2c Stage IV yes G2 negative present present dead 10 96 123 50 140 169
109 M 42 Surgery pT2 pN0 Stage II no G2 negative present present alive 10 221 105 - - 90
110 M 60 Surgery pT4 pN0 Stage IV no G2 negative absent present dead 37 568 535 - - 170
111 F 50 Surgery pT1 pN0 Stage I no G3 negative absent absent alive 55 178 208 - - 164
112 M 81 Surgery pT4 pN0 Stage IV no G1 positive absent present dead 49 180 335 - - 46
113 M 49 Surgery pT4 pN0 Stage IV no G2 negative absent present dead 21 296 392 - - 430
114 M 29 Surgery+CHT-RT pT4 pN2b Stage IV yes G2 negative absent present alive 54 129 456 48 187 98
115 F 62 Surgery pT4 pN2b Stage IV no G2 negative present present alive 53 20 125 34 227 111
116 M 78 Surgery pT2 pN0 Stage II no G2 negative absent present alive 53 116 64 - - 133
117 F 73 Surgery+RT pT4 pN2b Stage IV no G3 negative present absent alive 53 348 1089 64 288 132
118 M 67 Surgery+RT pT4 pN0 Stage IV no G3 negative present absent alive 51 217 167 - - 270
119 F 65 Surgery+RT pT2 pN0 Stage II no G3 positive absent absent alive 54 195 462 - - 184
101 M 65 Surgery+CHT-RT pT4 pN2b Stage IV yes G2 negative present present dead 11 99 106 29 124 222
121 F 41 Surgery pT2 pN1 Stage III no G2 negative present present alive 50 91 62 10 49 155
24 M 59 Surgery+RT pT3 pN2c Stage IV yes G2 negative present present dead 17 66 148 133 303 33
123 M 63 Surgery+RT pT4 pN0 Stage IV no G3 negative present absent alive 47 55 45 - - 74
124 F 88 Surgery pT2 pN0 Stage II no G3 negative present absent alive 42 120 558 - - 95
125 M 77 Surgery+RT pT4 pN2b Stage IV yes G2 negative absent present alive 45 49 94 38 81 79
126 M 59 Surgery+RT pT4 pN0 Stage IV no G3 positive present absent alive 44 93 201 - - 224
127 M 60 Surgery+CHT-RT pT4 pN2c Stage IV yes G3 negative absent absent dead 31 303 390 26 196 24
128 F 90 Surgery pT4 pN0 Stage IV no G1 negative absent present alive 44 464 272 - - 178
129 F 68 Surgery+RT pT4 pN0 Stage IV no G2 negative absent present alive 43 289 503 - - 210
18 M 64 Surgery+RT pT4 pN0 Stage IV no G3 negative present absent dead 82 92 65 - - 40
131 F 70 Surgery pT1 pN0 Stage I no G1 negative absent present alive 42 220 120 - - 31
132 M 62 Surgery+CHT-RT pT4 pN2b Stage IV yes G3 negative present absent alive 37 47 52 135 271 48
133 F 52 Surgery pT2 pN1 Stage III no G3 negative present absent alive 40 21 55 9 145 124
134 F 32 Surgery+CHT-RT pT1 pN2b Stage IV no G3 negative absent absent alive 41 26 43 49 145 54
135 M 76 Surgery+RT pT4 pN2b Stage IV no G3 negative present absent alive 40 152 80 162 126 174
136 M 52 Surgery+CHT-RT pT4 pN0 Stage IV no G2 negative present present alive 36 180 146 - - 53
137 M 57 Surgery+RT pT1 pN1 Stage III no G1 negative absent present alive 39 568 197 56 111 140
138 F 73 Surgery+RT pT4 pN0 Stage IV no G3 negative absent absent alive 38 280 208 - - 164
139 M 78 Surgery pT2 pN0 Stage II no G1 negative absent present alive 33 130 83 - - 130
55 F 34 Surgery pT2 pN0 Stage II no G2 negative absent present dead 18 42 146 - - 540
21 M 71 Surgery pT2 pN0 Stage II no G3 negative absent absent dead 73 38 102 - - 33
142 M 56 Surgery+RT pT1 pN0 Stage I no G2 positive present present alive 36 300 365 - - 78
143 F 55 Surgery+CHT-RT pT4 pN2b Stage IV no G3 negative present absent alive 34 159 292 24 51 nd
98 M 78 Surgery+RT pT4 pN2b Stage IV yes G2 negative present present dead 14 42 117 35 126 65
145 F 91 Surgery pT1 pN0 Stage I no G2 negative absent present alive 23 23 11 - - 115
146 M 65 Surgery+RT pT4 pN0 Stage IV no G2 negative absent present alive 30 960 1396 - - 264
147 F 76 Surgery+RT pT4 pN0 Stage IV no G2 positive absent present alive 25 94 283 - - 76
148 M 54 Surgery+CHT-RT pT4 pN0 Stage IV no G1 negative present present alive 33 276 775 - - 100
72 M 64 Surgery+CHT-RT pT2 pN2b Stage IV no G3 positive present absent dead 23 51 59 5 36 59
144 M 77 Surgery pT4 pN0 Stage IV no G2 positive present present dead 32 48 81 - - 148
151 F 48 Surgery pT1 pN0 Stage I no G2 negative absent present alive 26 81 260 - - 188
10 M 49 Surgery pT1 pN1 Stage III yes G3 negative present absent dead 36 58 38 8 144 206
153 M 66 Surgery+CHT-RT pT1 pN2b Stage IV yes G3 positive absent absent alive 30 88 164 36 118 55
154 F 62 Surgery+CHT-RT pT4 pN2b Stage IV yes G3 positive present absent alive 28 53 76 39 77 31
155 M 64 Surgery+CHT-RT pT4 pN0 Stage IV no G3 negative present absent alive 27 413 781 - - 354
156 M 67 Surgery pT1 pN0 Stage I no G2 negative present present alive 24 297 268 - - 172
157 F 66 Surgery+CHT-RT pT2 pN0 Stage II no G2 positive present present dead 12 99 157 - - 68
158 M 79 Surgery+RT pT4 pN0 Stage IV no G2 negative present present alive 27 121 111 - - 78
159 M 72 Surgery+CHT-RT pT4 pN2c Stage IV yes G3 positive absent absent alive 23 439 609 164 124 134
160 M 61 Surgery+CHT-RT pT4 pN2c Stage IV yes G3 positive present absent alive 27 101 400 56 201 87
11 F 60 Surgery+RT pT2 pN1 Stage III no G3 positive present absent dead 19 43 51 nd nd nd
58 M 56 Surgery+CHT-RT pT2 pN2b Stage IV yes G3 negative present absent dead 25 34 53 47 53 31
163 F 72 Surgery+RT pT4 pN1 Stage IV no G2 negative present present alive 23 67 237 63 85 79
35 M 75 Surgery pT1 pN1 Stage III no G3 negative absent absent dead 41 14 71 18 45 65
165 M 45 Surgery+RT pT4 pN0 Stage IV no G1 negative present present alive 22 488 764 - - 85
166 M 67 Surgery pT1 pN0 Stage I no G2 negative absent present dead 22 121 234 - - nd
167 F 81 Surgery+RT pT2 pN0 Stage II no G1 negative present present alive 18 186 546 - - 57
168 M 73 Surgery pT1 pN0 Stage I no G3 negative absent absent alive 20 262 192 - - 81
169 M 81 Surgery pT2 pN0 Stage II no G1 negative absent present alive 19 88 90 - - 66
170 F 64 Surgery pT4 pN1 Stage IV yes G2 negative absent present dead 6 134 269 122 84 98
171 F 55 Surgery+CHT-RT pT2 pN0 Stage II no G2 negative present present alive 19 286 758 - - 155
172 M 66 Surgery pT1 pN1 Stage III no G3 negative absent absent alive 18 221 126 nd 208 200
150 F 88 Surgery+RT pT4 pN2b Stage IV yes G3 positive absent absent dead 6 8 102 43 104 206
174 F 78 Surgery+RT pT4 pN0 Stage IV no G2 negative present present alive 20 18 21 - - 52
175 M 83 Surgery pT2 pN0 Stage II no G2 negative present present alive 17 85 100 - - 44
176 F 77 Surgery+RT pT4 pN1 Stage IV no G2 negative absent present alive 15 26 30 17 77 222
177 F 84 Surgery pT2 pN0 Stage II no G1 negative absent present alive 15 241 213 - - 28
178 M 66 Surgery pT2 pN0 Stage II no G1 negative absent present alive 15 12 12 - - 74
179 F 66 Surgery+CHT-RT pT4 pN0 Stage IV no G2 negative present present alive 16 190 154 - - 12
100 M 74 Surgery+RT pT4 pN2b Stage IV yes G2 positive absent present dead 53 25 38 151 153 89
181 M 81 Surgery+RT pT4 pN2b Stage IV no G2 negative present present dead 7 138 256 97 152 73
182 M 51 Surgery+CHT-RT pT4 pN0 Stage IV no G2 negative present present alive 15 324 217 - - 195
Supplementary table 4: summary statistics of digital microscopy analysis of CD66b+TANs in the OSCC cohort. 







Parameter   Mean Min Median Max S.D. 
  n° n° n° n° n° n° 
M-TDLN 220 2.6 1.0 2.0 13.0 2.4 
NM-TDLN 626 3.4 1.0 3.0 11.0 2.2 
  Tot area - mm2 mm2 mm2 mm2 mm2 mm2 
Area M-TDLN 16396 195.2 5.8 123.6 959.1 174.7 
Area M-TDLNM 8717 103.8 0.1 63.1 895.1 138.7 
Area M-TDLNP 7679 91.4 1.7 61.6 374.4 90.5 
Area NM-TDLN 19570 109.9 1.6 91.7 575.7 92.5 
   cells/mm2 cells/mm2 cells/mm2 cells/mm2 cells/mm2 
CD66b+TAN density M-TDLN  154.1 8.9 103.0 834.9 157.7 
CD66b+TAN density M-TDLNM  116.9 2.4 64.1 872.1 160.3 
CD66b+TAN density M-TDLNP  143.5 24.2 108.5 703.9 119.4 
CD66b+TAN density NM-TDLN  137.5 11.7 102.3 610.2 108.3 
        
Primary tumor CD66b+TAN analysis 
Parameter  Mean Min Median Max S.D. 
  Tot area - mm2 mm2 mm2 mm2 mm2 mm2 
Area tot PT  19041 104.6 6.8 94.4 329.6 70.6 
Area CT 12841 70.6 1.7 58.6 274.5 55.0 
Area IM 6200 34.1 2.5 30.4 136.5 20.3 
   cells/mm2 cells/mm2 cells/mm2 cells/mm2 cells/mm2 
CD66b+TAN density CT  231.3 6.4 155.4 1828.5 259.6 
CD66b+TAN density IM  288.6 9.8 194.3 2059.4 294.2 
Legend: TANs, tumor associated neutrophils; M-TDLN, metastatic tumor draining lymph nodes; NM-TDLN, non-metastatic tumor-draining lymph nodes;  
M, metastatic nests; P, surrounding lymph node tissue; PT, primary tumor; CT, center of the tumor; IM, invasive margin; S.D., standard deviation. 
Supplementary table 5: genes defining the PMN signature. 
Gene ID location aliases 
ARG1 Chromosome 6, NC_000006.12 (131573159..131584332)  
CEACAM3 Chromosome 19, NC_000019.10 (41796590..41811553) CD66D, CEA, CGM1, W264, W282 
CEACAM8 Chromosome 19, NC_000019.10 (42580243..42595157, complement) CD66b, CD67, CGM6, NCA-95 
CHI3L1 Chromosome 1, NC_000001.11 (203178931..203186794, complement) ASRT7, CGP-39, GP-39, GP39, HC-gp39, HCGP-3P, YK-
40, YKL-40, YKL40, YYL-40, hCGP-39 
CXCR1 Chromosome 2, NC_000002.12 (218162845..218166993, complement) C-C, C-C-CKR-1, CD128, CD181, CDw128a, CKR-1, 
CMKAR1, IL8R1, IL8RA, IL8RBA 
CXCR2 Chromosome 2, NC_000002.12 (218125290..218137253) CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB 
CYP4F3 Chromosome 19, NC_000019.10 (15640897..15661606) CPF3, CYP4F, LTB4H 
FCGR3B Chromosome 1, NC_000001.11 (161623196..161631963, complement) CD16, CD16A, CD16b, FCG3, FCGR3, FCGR3A, FCR-
10, FCRIII, FCRIIIb 
FPR2 Chromosome 19, NC_000019.10 (51752026..51770526) ALXR, FMLP-R-II, FMLPXA, FPRH1, FPRH2, FPRL1, 
HM63, LXA4R, FPR2 
HSPA6 Chromosome 1, NC_000001.11 (161524540..161526897) HSP70B' 
IL1R2 Chromosome 2, NC_000002.12 (101991805..102028544) CD121b, CDw121b, IL-1R-2, IL-1RT-2, IL-1RT2c, 
IL1RB, IL1R2 
KCNJ15 Chromosome 21, NC_000021.9 (38229915..38303126) IRKK, KIR1.3, KIR4.2 
MME Chromosome 3, NC_000003.12 (155024124..155183729) CALLA, CD10, CMT2T, NEP, SCA43, SFE 
MMP9 Chromosome 20, NC_000020.11 (46008908..46016561) CLG4B, GELB, MANDP2, MMP-9 
MMP25 Chromosome 16, NC_000016.10 (3045963..3060729) MMP-25, MMP20, MMP20A, MMPL1, MT-MMP 6, MT-
MMP6, MT6-MMP, MT6MMP, MTMMP6 
OLR1 Chromosome 12, NC_000012.12 (10158300..10172191, complement) CLEC8A, LOX1, LOXIN, SCARE1, SLOX1 
PGLYRP1 Chromosome 19, NC_000019.10 (46019153..46023298, complement) PGLYRP, PGRP, PGRP-S, PGRPS, TAG7, TNFSF3L 
S100A8 Chromosome 1, NC_000001.11 (153390032..153422583, complement) 60B8AG, CAGA, CFAG, CGLA, CP-10, L1Ag, MA387, 
MIF, MRP8, NIF, P8 
S100A9 Chromosome 1, NC_000001.11 (153357854..153361027) 60B8AG, CAGB, CFAG, CGLB, L1AG, LIAG, MAC387, 
MIF, MRP14, NIF, P14 
S100P Chromosome 4, NC_000004.12 (6693839..6697170) MIG9 
TNFAIP6 Chromosome 2, NC_000002.12 (151357592..151380048) TSG-6, TSG6 
TNFRSF10C Chromosome 8, NC_000008.11 (23102814..23117437) CD263, DCR1, DCR1-TNFR, LIT, TRAIL-R3, TRAILR3, 
TRID 
TREM1 Chromosome 6, NC_000006.12 (41267385..41286745, complement) CD354, TREM-1 
VNN3 Chromosome 6, NC_000006.12 (132722787..132734765, complement) HSA238982 
Supplementary table 6: Coefficients and p-value (unadjusted) for univariate linear models between 
pEMT global score and PMN genes expression (log2-RPKM). PMN genes with a significant beta in 
at least one comparison were highlighted as potentially associated to pEMT signature. 
 
  All samples Stage III/IV Stage I/II 
  Beta p-value Beta p-value Beta p-value 
ARG1 -0.0318 0.023 -0.0245 <0.01 -0.0318 0.023 
CEACAM3 -0.0374 0.173 -0.0153 0.365 -0.0374 0.173 
CEACAM8 -0.0372 0.218 -0.0577 <0.01 -0.0372 0.218 
CHI3L1 -0.0042 0.855 -0.0011 0.930 -0.0042 0.855 
CXCR1 0.0716 <0.01 0.078 <0.01 0.0716 <0.01 
CXCR2 -0.0161 0.458 -0.0118 0.404 -0.0161 0.458 
CYP4F3 -0.0766 <0.01 -0.0641 <0.01 -0.0766 <0.01 
FCGR3B 0.0068 0.767 0.0238 0.044 0.0068 0.767 
FPR2 0.0045 0.852 0.0605 <0.01 0.0045 0.852 
HSPA6 0.0022 0.958 0.0035 0.865 0.0022 0.958 
IL1R2 -0.0139 0.584 0.0107 0.476 -0.0139 0.584 
KCNJ15 0.0934 <0.01 0.0976 <0.01 0.0934 <0.01 
MME 0.0518 0.018 0.0648 <0.01 0.0518 0.018 
MMP25 -0.0389 0.348 0.0133 0.517 -0.0389 0.348 
MMP9 0.0728 <0.01 0.0824 <0.01 0.0728 <0.01 
OLR1 0.0512 0.023 0.0466 <0.01 0.0512 0.023 
PGLYRP1 -0.0398 0.069 -0.0281 0.049 -0.0398 0.069 
S100A8 -0.0169 0.437 -0.0138 0.238 -0.0169 0.437 
S100A9 -0.0145 0.514 -0.0154 0.231 -0.0145 0.514 
S100P -0.0594 <0.01 -0.0299 <0.01 -0.0594 <0.01 
TNFAIP6 0.1188 <0.01 0.1369 <0.01 0.1188 <0.01 
TNFRSF10C 0.0058 0.840 0.0389 0.051 0.0058 0.840 
TREM1 0.0588 0.040 0.0437 <0.01 0.0588 0.040 
VNN3 -0.0425 0.023 -0.0183 0.088 -0.0425 0.023 
 
 
Supplementary table 7: Clinical data of prospective cohort for flow cytometry analysis and reverse transcription quantitative real-time PCR 
analysis. 
 
Code Gender Age Site Subsite T category N category M category Stage Grading 
H&N_Blood_001 M 81 Head & Neck OC T2 N0 M0 II G1 
H&N_Blood_002 F 64 Head & Neck OC T4a N1 M0 IVa G2 
H&N_Blood_003 M 68 Head & Neck OC T2 N1 M0 III G2 
H&N_Blood_004 F 55 Head & Neck OC T2 N0 M0 III G2 
H&N_Blood_005 F 78 Head & Neck OC T4a N0 M0 IVa G2 
H&N_Blood_006 M 83 Head & Neck OC T2 N0 M0 II G1-G2 
H&N_Blood_007 F 84 Head & Neck OC T1 N0 M0 I G1 
H&N_Blood_008 M 66 Head & Neck OC T1 N0 M0 I G1 
H&N_Blood_009 F 69 Head & Neck OC T4a N0 M0 IVa G3 
H&N_Blood_010 M 55 Head & Neck OC T4a N0 M0 IVa G2 
H&N_Blood_011 M 73 Head & Neck OC T4a N2b M1 IVc G2 
H&N_Blood_012 M 56 Head & Neck L T3 N2c M0 IVa N.A. 
H&N_Blood_013 M 81 Head & Neck OC T4a N2b M0 IVa G1-G2 
H&N_Blood_014 M 89 Head & Neck OC T1 N1 M0 III G2 
H&N_Blood_015 M 74 Head & Neck L T2 cN3 M1 IVc G2 
 
Legend: M, male; F, female; OC, oral cavity; L, larynx; N.A, not available. 
  




















Reagent Clone Dilution Source 
PRIMARY ANTIBODIES 
(IHC) 
   
Active Caspase-3  Rabbit pAb 1:600 R&D Systems 
Arginase-1 SP156 1:100 Cell Marque 
BDCA2/CD303 124B3.13 1:75 Dendritics 
CD3 SP7 1:100 Thermo Scientific 
CD8 C8/144B 1:30 Agilent 
CD11b Rabbit pAb 1:300 Sigma-Aldrich 
CD14 7 1:50 Leica Biosystems 
CD15 Carb-3 1:50 Agilent 
CD16 2H7 1:100 Leica Biosystems 
CD31 1A10 1:50 Leica Biosystems 
CD34 QBEND/10 1:200 Leica Biosystems 
CD56 123C3.D5 1:50 Thermo Scientific 
CD66b G10F5 1:200 BioLegend 
CD68 PG-M1 1:200 Agilent 
CD163 10D6 1:50 Thermo Scientific 
CLA/Heca 452 HECA-452 1:50 BD Pharmingen 
Claudin 4 3E2C1 1:100 Invitrogen 
c/EBP beta H-7 1:100 Santa Cruz Biotechnology 
DD1 DD1 1:60 K.S (University Hospital Heidelberg) 
ERG EPR3864(2) 1:1200 Novus Biologicals 
Factor VIII Rabbit pAb 1:100 Thermo Scientific 
Foxp3 PCH101 1:200 eBioscience 
HLADR, DP, DQ and DX V1030 1:500 Biomeda corp. 
Keratin 7 OV-TL 12/30 1:100 Agilent 
Ki-67 30-9 undiluted Ventana 
Lyve1 Rabbit pAb 1:75 Reliatech 
Myeloperoxidase Rabbit  pAb 1:6000 Agilent 
Podoplanin D2-40 1:50 Agilent 
pSTAT3 (Tyr705) D3A7 1:120 Cell Signaling Tech. 
S100 Rabbit  pAb 1:3000 Agilent 
S100A9 Rabbit  pAb 1:2500 Sigma-Aldrich 
TCR C gamma M1 gamma 3.20 1:300 Thermo Scientific 
 
Reagent Clone Isotype Source 
PRIMARY ANTIBODY    
(FC)    
AlexaFluor647 anti-human CCR7 G043H7 mIgG2a Biolegend 
AlexaFluor647 anti-human CXCR2 5E8/CXCR2 mIgG1 Biolegend 
AlexaFluor647 mouse IgG1 MOPC-21  Biolegend 
AlexaFluor647 mouse IgG2a MOPC-173  Biolegend 
APC anti-human CD11c MJ-27G12 mIgG2b Miltenyi Biotec 
APC anti-human CD54 REA266 Recombinant human IgG1 Miltenyi Biotec 
APC anti-human CD62L 145/15 mIgG1 Miltenyi Biotec 
APC anti-human CXCR1 8F1/CXCR1 mIgG2b Biolegend 
APC anti-human CXCR4 12G5 mIgG2a Biolegend 
APC-Cy7 anti-human CD16 3G8 mIgG1 Biolegend 
APC-Cy7 anti-human CD25 BC96 mIgG1 Biolegend 
APC-Cy7 HLA-DR L243 mIgG2a Biolegend 
APC mouse IgG2a MOPC-173  Biolegend 
APC mouse IgG2b MG2b-57  Biolegend 
APC REA control  REA266  Miltenyi Biotec 
Brilliant Violet 421 anti-human CD4 SK3 mIgG1 Biolegend 
Brilliant Violet 510 anti-human CD45  HI30 mIgG1 Biolegend 
BV421 anti-human CD274 MIH1 mIgG1 BD Biosciences 
FITC anti-human CD11a HI111 mIgG1 BD Biosciences 
FITC anti-human CD66b G10F5 mIgM Biolegend 
FITC anti-human BDCA2/CD303 AC144 mIgG1 Miltenyi Biotec 
PE anti-human C5aR S5/1 mIgG2a Biolegend 
PE anti-human CD10 HI10a mIgG1 Biolegend 
PE anti-human CD56 5.1H11 mIgG1 Biolegend 
PE-Cy7 anti-human CD3 UCHT1 mIgG1 Biolegend 
PE-Cy7 anti-human CD11b ICRF44 mIgG1 Biolegend 
PE-Cy7 anti-human CD19 HIB19 mIgG1 Biolegend 
PE-Cy7 anti-human CD127 HIL-7R-M21 mIgG1 BD Biosciences 
PE-Vio770 anti-human CD11b REA713 Recombinant human IgG1 Miltenyi Biotec 
PE-Vio770 anti-human 	CD62L 145/15 mIgG1 Miltenyi Biotec 
Vioblue anti-human CD14 TÜK4 mIgG2a Miltenyi Biotec 
    
Supplementary table 9: List of the primer pairs used for reverse transcription quantitative real-time PCR (RT-qPCR).  
 
gene forward primer reverse primer 
CEACAM8/CD66b 5’-GCCAGTTCAGCGTACATCC-3’ 5’-TTCCTTGTGACACTGAGTAGAG-3’ 
CXCR1 5’- GGTGCTTCAGTTAGATCAAACC-3’ 5’-CCAGGTTCAGCAGGTAGAC-3’ 
FCGRB3 5’-TCAAGTTAAGCTAAGTGAACAGA-3’ 5’-ACAAAGCTATACAGGAACTAGAC-3’ 
FPR2 5’-TAAGAAGAGTCCGCTGACAAC-3’ 5’-GCCAATCCCCTAACAGAAAC-3’ 
KCNJ15 5’-AGTGAGTGACCAGTGTTTCCA-3’ 5’-GCCATCCACTTTGTCAATTCTC-3’ 
MME/CD10 5’-TCAAGCATACAGAGCCTATCAG-3 5’-TCCCAATAATCCTGAAATTGCC-3’ 
MMP9 5’-TGTTCAAGGATGGGAAGTACTG-3’ 5’-CTCCTCAAAGACCGAGTCCA-3’ 
OLR1 5’-CATGCAATTATCCCAGGTGTC-3’ 5’-GGATTTCTCATTCAGCTTCCGA-3’ 
RPL32 5’-AGGGTTCGTAGAAGATTCAAGG-3’ 5’-GGAAACATTGTGAGCGATCTC-3’ 
TNFAIP6 5’-ATGCCTATTGCTACAACCCAC-3’ 5’-TCATCTCCACAGTATCTTCCCA-3’ 
TNFRSF10C 5’-CAACGCTTCCAACAATGAACC-3’ 5’-ACTAGGGCACCTGCTACAC-3’ 
 
 
 
